Is there a biosimilar for Humira?

The Food and Drug Administration recently approved Cyltezo (adalimumab-adbm), the first interchangeable biosimilar product of Humira (adalimumab). Humira is an injectable drug widely used to manage symptoms of rheumatoid arthritis (RA) and several other autoimmune conditions.

Is Humira made by Pfizer?

Pfizer’s Abrilada, a biosim to AbbVie’s megablockbuster Humira, won FDA approval Monday, becoming the 25th biosim to score a green light from the agency.

What has replaced Humira?

Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with (may be substituted for), its reference product Humira (adalimumab) for Cyltezo’s approved uses.

Is Humira and adalimumab the same thing?

Amjevita (adalimumab-atto) was the first Humira (adalimumab) biosimilar approved by the FDA. FDA approved biosimilars to Humira include: Amjevita (adalimumab-atto) Cyltezo (adalimumab-adbm)…Official Answer.

Indication Humira Amjevita
Rheumatoid Arthritis (RA) adults adults

How much do Humira biosimilars cost?

Entry Barriers for Biosimilars AbbVie has raised the price of Humira by 470% since it entered the market in 2003. It now costs about $77,000 for a year’s supply, according to a report from a House Oversight Committee.

How many Humira biosimilars are there?

Eight more biosimilars — as copies of biologic drugs are called — are expected to become available over the course of 2023, putting AbbVie under pressure….Expected U.S. launch dates of Humira biosimilars.

Drugmakers(s) Biosimilar approved in US? Expected launch date
Viatris Yes, Hulio July 31, 2023

What drug company owns Humira?

AbbVie is a research-based biopharmaceutical company. It spun off of Abbott Laboratories in 2013. The company has had a successful start in its first five years in the industry. Its blockbuster drug Humira brought in billions.

Who makes Humira pen?

In 2006 AbbVie launched the Humira Pen, a self-injecting device, and it is currently in Phase III clinical trials for three additional indications – unspecified arthritis, peripheral spondyloarthritis and pyoderma gangrenosum.

Is there a safer alternative to Humira?

With the FDA’s decision, Cyltezo (adalimumab-adbm) can now be made available to patients with rheumatoid and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis who have a prescription for Humira (adalimumab).

Why is Humira so popular?

Studies have shown Humira can reduce symptoms of psoriatic arthritis within 3 months, and clear 75% of associated skin psoriasis symptoms within 6 months for the majority of patients. The biosimilars to Humira are also approved for psoriatic arthritis.

How long do you stay on Humira?

Always follow your doctor’s instructions about when and how often to use Humira. Your dose for Humira can also vary and depends on the condition being treated. However, many patients stay on Humira for years. In some cases, your doctor may decide to lower your dose or stop your treatment all together.